Amgen Inc. with ticker code (AMGN) have now 26 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $405.00 and $200.00 and has a mean target at $334.54. Given that the stocks previous close was at $321.91 and the analysts are correct then we can expect a percentage increase in value of 3.9%. There is a 50 day moving average of $323.61 and the 200 moving average now moves to $306.88. The market cap for the company is 174.85B. The stock price is currently at: $325.28 USD
The potential market cap would be $181,708,852,069 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 41.49, revenue per share of $60.64 and a 4.6% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
